Sana Biotechnology Leadership

Christian Hordo is an Exec VP/Chief Business Officer at SANA BIOTECHNOLOGY INC. and is based in Seattle, Washington. He has worked as Vice President, Head of Business Development at Juno Therapeutics Inc; Manager, R&D Finance at Genentech Inc.; and Vice President, Myeloma Program Lead at Juno Therapeutics Inc. Christian attended University of Toronto between 2004 and 2007, Harvard Business School between 2008 and 2010, and McGill University between 2000 and 2004.

Robin Andrulevich is currently the Executive Vice President and Chief People Officer at Sana Biotechnology. Robin has more than 25 years of experience in human resources and operations at high-growth companies. Most recently, Robin served as the Senior Vice President of People at Juno Therapeutics. She has also held several key senior leadership roles in human resources and talent at Amazon and Google. She has worked in early-and mid-stage venture capital with firms including Madrona Venture Group and Union Square Ventures. Robin earned her B.A. in communications science from the University of Connecticut.

Chad has over 20 years of experience leading cutting-edge research groups and translating early discoveries into therapies. His prior roles include co-founder and Chief Scientific Officer at Sana Biotechnology and co-founder and Head of Research at CRISPR Therapeutics. Chad has also played an early role in the launch of several gene and cell therapy companies including, BlueRock Therapeutics, Vesigen Therapeutics, Metagenomi, and Vita Therapeutics.

Chad received his BA and BS from the University of Kansas. He received his Ph.D. from the University of Texas Southwestern. In 2006 he was named a Stowers Medical Investigator. In 2008, he became a Professor at Harvard University, Harvard Medical School, and the Harvard Stem Cell Institute, where he led academic research groups and taught.

Edward John Rebar is an American biologist. Rebar is the senior vice president and chief technology officer of Sangamo Therapeutics. He researches the use of zinc fingers as a protein platform.

Christian Hordo is an Exec VP/Chief Business Officer at SANA BIOTECHNOLOGY INC. and is based in Seattle, Washington. He has worked as Vice President, Head of Business Development at Juno Therapeutics Inc; Manager, R&D Finance at Genentech Inc.; and Vice President, Myeloma Program Lead at Juno Therapeutics Inc. Christian attended University of Toronto between 2004 and 2007, Harvard Business School between 2008 and 2010, and McGill University between 2000 and 2004.

Robin Andrulevich is currently the Executive Vice President and Chief People Officer at Sana Biotechnology. Robin has more than 25 years of experience in human resources and operations at high-growth companies. Most recently, Robin served as the Senior Vice President of People at Juno Therapeutics. She has also held several key senior leadership roles in human resources and talent at Amazon and Google. She has worked in early-and mid-stage venture capital with firms including Madrona Venture Group and Union Square Ventures. Robin earned her B.A. in communications science from the University of Connecticut.

Chad has over 20 years of experience leading cutting-edge research groups and translating early discoveries into therapies. His prior roles include co-founder and Chief Scientific Officer at Sana Biotechnology and co-founder and Head of Research at CRISPR Therapeutics. Chad has also played an early role in the launch of several gene and cell therapy companies including, BlueRock Therapeutics, Vesigen Therapeutics, Metagenomi, and Vita Therapeutics.

Chad received his BA and BS from the University of Kansas. He received his Ph.D. from the University of Texas Southwestern. In 2006 he was named a Stowers Medical Investigator. In 2008, he became a Professor at Harvard University, Harvard Medical School, and the Harvard Stem Cell Institute, where he led academic research groups and taught.